Business

Mylan has announced that the United States District Court for the Northern District of West Virginia granted a Mylan motion for partial summary judgment and found that Teva's generic formoterol fumarate inhalation solution infringes US Patent No. 6,667,344 on Mylan's Perforomist inhalation solution. The court will hear arguments on other issues in the case later this … [Read more...] about Court finds that Teva’s generic Perforomist infringes on Mylan patent

Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company says that it will also use the funding "to invest in third-party manufacturers and the supply chain in … [Read more...] about Insmed announces public offering of common stock

The US District Court for the Southern District of New York has issued a final judgment and order affirming the validity of five patents related to Mylan's Perforomist formoterol fumarate inhalation solution and stating that Sunovion's Brovana inhalation solution infringes the Mylan patents. Mylan had appealed after the five patents were invalidated in March 2012; two … [Read more...] about Court issues final judgment in Perforomist case in favor of Mylan

According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn's "profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)" and "an increasing demand worldwide for more patient friendly drug delivery methods for optimum … [Read more...] about Melbourn Scientific acquired by Intertek

According to RDD Online, the RDD China meeting scheduled to take place October 16-18, 2013 in Beijing has been cancelled due to "contractual problems which made it impossible for RDD to guarantee the quality of the conference and ensure that all exhibitors and workshop presenters would be treated equitably." The meeting, which was to be co-sponsored by the Chinese … [Read more...] about RDD China cancelled

Avanir Pharmaceuticals has paid $20 million up front to OptiNose for an exclusive North American license for development and commercialization of OptiNose's intranasal low-dose sumatriptan powder for the treatment of acute migraines. OptiNose could receive an additional $90 million in milestone payments and, if the product is approved, Avanir will make royalty … [Read more...] about Avanir makes deal with OptiNose for intranasal sumatriptan powder

Jabil Circuit has announced the completion of its $665 million acquisition of contract plastics manufacturer Nypro, which makes dry powder inhalers and nasal spray pumps for pharmaceutical companies among other products. According to Jabil, it will keep the Nypro name and will absorb approximately 10,000 Nypro employees. Nypro will keep its headquarters in Clinton, … [Read more...] about Jabil completes acquisition of Nypro

Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015. Valeant will pay Zogenix a quarterly service fee based on a percentage of sales exceeding a specified baseline. Zogenix CEO Roger L. Hawley … [Read more...] about Zogenix to co-promote Migranal nasal spray in US

The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis. The team's research proposal was titled "A tight squeeze: … [Read more...] about RespiTech gets grant for inhaled pulmonary fibrosis treatment

Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary … [Read more...] about Kamada gets new patents for inhaled AAT